The Systemic Synuclein Sampling Study: Toward a Biomarker for Parkinson’s Disease

Authors:
  • T(the Systemic Synuclein Sampling Study (S4)
    the Systemic Synuclein Sampling Study (S4)

Abstract
The search for a biomarker for Parkinson's disease (PD) has led to a surge in literature describing peripheral α-synuclein (aSyn) in both biofluids and biopsy/autopsy tissues. Despite encouraging results, attempts to capitalize on this promise have fallen woefully short. The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for PD. S4 will evaluate aSyn in multiple tissues and biofluids within the same subject and across the disease spectrum to identify the optimal biomarker source and provide vital information on the evolution of peripheral aSyn throughout the disease. Additionally, S4 will correlate the systemic aSyn profile with an objective measure of nigrostriatal dopaminergic function furthering our understanding of the pathophysiological progression of PD.
Funding Information
  • Michael J Fox foundation for PD, NINDS PD Biospecimen Review Access Committee
  • The University of Toronto McLaughlin Centre
  • TEVA-Pharma, Desitin, Boehringer Ingelheim, GE Healthcare
  • BMBF, EU, Deutsche Parkinson Vereinigung, Michael J Fox Foundation
  • NIH, the Michael J Fox Foundation and the state of Arizona
  • NIH, the Michael J Fox Foundation and serves on the Steering Committee

This publication has 57 references indexed in Scilit: